Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
6
Neutral
4
Bullish
4
Bearish
6
Neutral
4
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
J.B. Chemicals & Pharmaceuticals Limited is a leading pharmaceutical company established in 1976, heavily engaged in the manufacture and marketing of diverse pharmaceutical formulations, herbal remedies, and APIs.
The company continues to be one of the fastest growing organizations in the Indian pharmaceutical market, demonstrating superior performance with notable growth in key brands such as Cilacar, Sporlac, and Razel.
J.B. Chemicals recently expanded through strategic acquisitions, including the Azmarda brand from Novartis, which fortifies its presence in the cardiology market.
The company places a strong focus on expanding its domestic and international presence with a robust order book, driving both revenue and profit growth significantly above the industry average.
Pharmaceuticals & Biotechnology
Pharmaceuticals
36,155 Cr
Low Risk
51.0
34.1
2.1
8.7
2,299.95
1,603.05
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1591.00 | 40,924 Cr | 35.86 | 5.07 | 0.37 | 14.15 | 18.58 | 9.63 | ||
3128.00 | 39,230 Cr | 37.15 | 8.67 | 0.89 | 23.33 | 29.09 | 17.16 | ||
2255.15 | 38,031 Cr | 37.02 | 3.67 | 0.87 | 9.92 | 14.02 | 8.21 | ||
2258.20 | 36,155 Cr | 50.96 | 8.69 | 0.98 | 17.06 | 22.99 | 14.28 | ||
2115.70 | 35,621 Cr | 34.38 | 15.71 | 2.71 | 45.69 | 61.23 | 23.96 | ||
1734.25 | 31,912 Cr | 34.52 | 6.45 | 0.21 | 18.67 | 21.76 | 9.79 | ||
1934.95 | 31,312 Cr | 147.01 | 6.34 | 0.00 | 5.75 | 7.39 | 2.31 | ||
| Median: 7 Co. | — | 2115.70 | 36,155 Cr | 37.02 | 6.45 | 0.87 | 17.06 | 21.76 | 9.79 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) is currently trading at 2,258.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
J.B. Chemicals & Pharmaceuticals Limited is a leading pharmaceutical company established in 1976, heavily engaged in the manufacture and marketing of diverse pharmaceutical formulations, herbal remedies, and APIs. The company continues to be one of the fastest growing organizations in the Indian pharmaceutical market, demonstrating superior performance with notable growth in key brands such as Cilacar, Sporlac, and Razel. J.B. Chemicals recently expanded through strategic acquisitions, including the Azmarda brand from Novartis, which fortifies its presence in the cardiology market. The company places a strong focus on expanding its domestic and international presence with a robust order book, driving both revenue and profit growth significantly above the industry average.
Over the past 52 weeks, J B Chemicals & Pharmaceuticals Ltd has traded between a low of ₹1,603.05 and a high of ₹2,299.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
J B Chemicals & Pharmaceuticals Ltd has a market capitalization of approximately 36,155.41. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
J B Chemicals & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 50.96 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 36,155.41 Cr, J B Chemicals & Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
J B Chemicals & Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of J B Chemicals & Pharmaceuticals Ltd is 50.96. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board approved an interim dividend of ₹12.70 per equity share (face value ₹1) for FY2025-26.
The provided text cites consolidated Q4 FY25 revenue of about ₹949.5 crore and net profit (PAT) of about ₹146 crore, up roughly 10% and 15%-16% year-on-year, respectively.
NCLT Ahmedabad directed both companies to convene meetings of equity shareholders for the proposed amalgamation under Sections 230-232 of the Companies Act, 2013, with a quorum of 30 shareholders.
It directed both companies to convene equity shareholder meetings for the amalgamation under Sections 230-232, to be held within 45 days via VC/OVAM, with specified meeting oversight appointments.
Management Resignation
J.B. Chemicals disclosed that Mr. Bhushan Sachdev has resigned as Executive Vice President – Supply Chain, ceasing with effect from close of business on June 12, 2026 (last working day per policy June 13, 2026).
Senior management change
J.B. Chemicals & Pharmaceuticals announced that Mr. Bhushan Sachdev has resigned and ceased as Executive Vice President – Supply Chain Management with effect from close of business on June 12, 2026 (last working day per policy June 13, 2026).
